1
|
Hobbs KJ, Le Sueur ANV, Burke MJ, Cooper BL, Sheats MK, Ueda Y. Feasibility of hemoperfusion using extracorporeal therapy in the horse. Front Vet Sci 2024; 11:1414426. [PMID: 38803798 PMCID: PMC11128652 DOI: 10.3389/fvets.2024.1414426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2024] [Accepted: 04/30/2024] [Indexed: 05/29/2024] Open
Abstract
Objective Develop, implement, and monitor for adverse effects of, a novel hemoperfusion therapy in adult horses. Methods A prospective, observational feasibility study using three healthy adult horses from the North Carolina State University teaching herd. Health status was determined by physical exam, complete blood count, coagulation panel, and serum biochemistry. Each horse was instrumented with a 14 Fr × 25 cm double-lumen temporary hemodialysis catheter and underwent a 240 min polymer-based hemoperfusion session. Horses were administered unfractionated heparin to maintain anti-coagulation during the session. Given the novelty of this therapy in horses, each horse was treated as a learning opportunity that informed an iterative process of protocol development and modification. Measurements and main results Our long-term goal is to investigate potential clinical applications of hemoperfusion in horses, including cytokine reduction in horses with severe SIRS/sepsis. Horses were monitored for changes in clinical exam, biochemistry and hematology parameters. Additionally, cytokines were quantified to determine whether extracorporeal hemadsorption therapy alone caused an inflammatory response. Our results show that hemoperfusion therapy was associated with decreased platelet counts and serum albumin concentration. There was no significant change in plasma cytokine concentrations with hemoperfusion therapy. In one horse, the cytokine concentrations decreased, as previously reported with hemoperfusion therapy in humans. Hypothesis We hypothesized that hemoperfusion therapy could be performed in healthy adult horses without significant adverse effects. Conclusion Polymer-based hemoperfusion is a feasible extracorporeal therapy (ECT) modality for adult horses. Additional studies are needed to further establish clinical protocols, as well as establish efficacy of polymer-based hemoperfusion for treatment of various conditions in horses, including intoxications, immune-mediated conditions, and sepsis.
Collapse
|
2
|
Reffo I, Domini M, Cevolani M, Del Fabro G, Rufolo D, Venturini S, Pinciroli L, Tonin D, Avolio M, Crapis M, Basaglia G, Balbi M, Nadalin G. Clostridium perfringens-induced massive hemolysis treatment with blood purification to target toxins: a case report. CEN Case Rep 2024:10.1007/s13730-024-00857-3. [PMID: 38436873 DOI: 10.1007/s13730-024-00857-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2023] [Accepted: 02/07/2024] [Indexed: 03/05/2024] Open
Abstract
Clostridium perfringens can rarely cause severe systemic infections, usually from an abdominal source, associated with massive hemolysis, which is usually fatal. Hemolytic anemia and acute renal injury resulting from toxin action are critical for the development of multiple organ dysfunction syndrome (MODs), making this condition a real emergency, requiring multispecialty skills and aggressive multimodal therapies. We herein describe a case of septic shock from acute cholecystitis with massive hemolysis caused by C. perfringens in a 55 year-old man that was successfully treated with early blood purification and continuous renal replacement therapy (CRRT) along with antibiotic therapy and surgery. The effect of the enormous amount of toxins produced by Clostridium which elicit a strong cytokine response and the damage caused by the hemolysis products are the main pathogenetic mechanisms of this rare but lethal clinical entity. The main goal of treatment is to remove toxins from plasma, block toxin action, and further production by achieving bacterial killing with antimicrobial agents and controlling the infectious focus, remove waste products and prevent or limit multiorgan damage. Blood purification techniques play an important role due to a strong pathophysiological rationale, as they can remove toxins and cytokines as well as cell-free products from plasma and also replace renal function. Although this condition is rare and robust data are lacking, blood purification techniques for C. perfringens-induced massive hemolysis are promising and should be further explored.
Collapse
Affiliation(s)
- I Reffo
- Anaesthesia and Intensive Care Department, Azienda Sanitaria Friuli Occidentale "Santa Maria Dei Battuti" Hospital, Via Savorgnano 2, San Vito al Tagliamento, 33078, Pordenone, Italy.
| | - M Domini
- Anaesthesia and Intensive Care Department, Azienda Sanitaria Friuli Occidentale "Santa Maria Dei Battuti" Hospital, Via Savorgnano 2, San Vito al Tagliamento, 33078, Pordenone, Italy
| | - M Cevolani
- Internal Medicine Department, Azienda Sanitaria Friuli Occidentale "Santa Maria dei Battuti" Hospital, San Vito al Tagliamento, Pordenone, Italy
| | - G Del Fabro
- Infectious Diseases Department, Azienda Sanitaria Friuli Occidentale "Santa Maria degli Angeli" Hospital, Pordenone, Italy
| | - D Rufolo
- Anaesthesia and Intensive Care Department, Azienda Sanitaria Friuli Occidentale "Santa Maria Dei Battuti" Hospital, Via Savorgnano 2, San Vito al Tagliamento, 33078, Pordenone, Italy
| | - S Venturini
- Infectious Diseases Department, Azienda Sanitaria Friuli Occidentale "Santa Maria degli Angeli" Hospital, Pordenone, Italy
| | - L Pinciroli
- General Surgery Department, Azienda Sanitaria Friuli Occidentale "Santa Maria dei Battuti" Hospital, San Vito Al Tagliamento, Pordenone, Italy
| | - D Tonin
- General Surgery Department, Azienda Sanitaria Friuli Occidentale "Santa Maria dei Battuti" Hospital, San Vito Al Tagliamento, Pordenone, Italy
| | - M Avolio
- Microbiology Department, Azienda Sanitaria Friuli Occidentale "Santa Maria degli Angeli" Hospital, Pordenone, Italy
| | - M Crapis
- Infectious Diseases Department, Azienda Sanitaria Friuli Occidentale "Santa Maria degli Angeli" Hospital, Pordenone, Italy
| | - G Basaglia
- Microbiology Department, Azienda Sanitaria Friuli Occidentale "Santa Maria degli Angeli" Hospital, Pordenone, Italy
| | - M Balbi
- Internal Medicine Department, Azienda Sanitaria Friuli Occidentale "Santa Maria dei Battuti" Hospital, San Vito al Tagliamento, Pordenone, Italy
| | - G Nadalin
- Anaesthesia and Intensive Care Department, Azienda Sanitaria Friuli Occidentale "Santa Maria Dei Battuti" Hospital, Via Savorgnano 2, San Vito al Tagliamento, 33078, Pordenone, Italy
| |
Collapse
|
3
|
De Rosa S, Ferrari F, Greco M, Pota V, Umbrello M, Cotoia A, Pasin L, Nalesso F, Paternoster G, Villa G, Lassola S, Miori S, Sanna A, Cantaluppi V, Marengo M, Valente F, Fiorentino M, Brunori G, Bellani G, Giarratano A. The use of extracorporeal blood purification therapies and sequential extracorporeal support in patients with septic shock (EROICASS): a study protocol for a national, non-interventional, observational multicenter, prospective study. JOURNAL OF ANESTHESIA, ANALGESIA AND CRITICAL CARE 2024; 4:16. [PMID: 38409062 PMCID: PMC10898122 DOI: 10.1186/s44158-024-00153-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/27/2024] [Accepted: 02/16/2024] [Indexed: 02/28/2024]
Abstract
BACKGROUND Septic shock, a critical condition characterized by organ failure, presents a substantial mortality risk in intensive care units (ICUs), with the 28-day mortality rate possibly reaching 40%. Conventional management of septic shock typically involves the administration of antibiotics, supportive care for organ dysfunction, and, if necessary, surgical intervention to address the source of infection. In recent decades, extracorporeal blood purification therapies (EBPT) have emerged as potential interventions aimed at modulating the inflammatory response and restoring homeostasis in patients with sepsis. Likewise, sequential extracorporeal therapy in sepsis (SETS) interventions offer comprehensive organ support in the setting of multiple organ dysfunction syndrome (MODS). The EROICASS study will assess and describe the utilization of EBPT in patients with septic shock. Additionally, we will evaluate the potential association between EBPT treatment utilization and 90-day mortality in septic shock cases in Italy. METHODS The EROICASS study is a national, non-interventional, multicenter observational prospective cohort study. All consecutive patients with septic shock at participating centers will be prospectively enrolled, with data collection extending from intensive care unit (ICU) admission to hospital discharge. Variables including patient demographics, clinical parameters, EBPT/SETS utilization, and outcomes will be recorded using a web-based data capture system. Statistical analyses will encompass descriptive statistics, hypothesis testing, multivariable regression models, and survival analysis to elucidate the associations between EBPT/SETS utilization and patient outcomes. CONCLUSIONS The EROICASS study provides valuable insights into the utilization and outcomes of EBPT and SETS in septic shock management. Through analysis of usage patterns and clinical data, this study aims to guide treatment decisions and enhance patient care. The implications of these findings may impact clinical guidelines, potentially improving survival rates and patient outcomes in septic shock cases.
Collapse
Affiliation(s)
- Silvia De Rosa
- Centre for Medical Sciences (CISMed), University of Trento, 38122, Trento, Italy.
- Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy.
- International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy.
| | - Fiorenza Ferrari
- International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy
- Department of Anesthesia, Intensive Care and Emergency, Fondazione IRRCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, Italy
| | | | - Vincenzo Pota
- Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Michele Umbrello
- Section of Resuscitation and Anesthesia, ASST Ovest Milanese, Ospedale Nuovo Di Legnano, Legnano, Milan, Italy
| | - Antonella Cotoia
- Department of Medical and Surgical Sciences, Anesthesia and Intensive Care Unit, University of Foggia, Foggia, Italy
| | - Laura Pasin
- International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy
| | - Federico Nalesso
- Nephrology, University Hospital, University of Padova, Padua, Italy
| | - Gianluca Paternoster
- Division of Cardiac Resuscitation, Cardiovascular Anesthesia and Intensive Care, San Carlo Hospital, Potenza, Italy
| | - Gianluca Villa
- Department of Health Sciences, Intensive Care and Pain Medicine Section of Anesthesia, University of Florence, Florence, Italy
| | - Sergio Lassola
- Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy
| | - Sara Miori
- Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy
| | - Andrea Sanna
- Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy
| | - Vicenzo Cantaluppi
- Department of Translational Medicine, Nephrology and Kidney Transplantation Unit, "Maggiore Della Carità" University Hospital, University of Piemonte Orientale (UPO), Novara, Italy
| | - Marita Marengo
- Department of Specialist Medicine, Nephrology and Dialysis Unit, Azienda Sanitaria Locale (ASL) CN1, Cuneo, Italy
| | - Fabrizio Valente
- Nephrology and Dialysis, Santa Chiara Regional Hospital, APSS, Trento, Italy
| | - Marco Fiorentino
- Department of Surgical, Oncological, and Oral Science (Di.Chir.On.S.), University of Palermo, Palermo, Italy
| | - Giuliano Brunori
- Centre for Medical Sciences (CISMed), University of Trento, 38122, Trento, Italy
- Nephrology and Dialysis, Santa Chiara Regional Hospital, APSS, Trento, Italy
| | - Giacomo Bellani
- Centre for Medical Sciences (CISMed), University of Trento, 38122, Trento, Italy
- Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy
| | - Antonino Giarratano
- Department of Surgical, Oncological, and Oral Science (Di.Chir.On.S.), University of Palermo, Palermo, Italy
- Department of Anesthesia, Intensive Care, and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy
| |
Collapse
|
4
|
García-Villegas R, Arni S. Hemoadsorption in Organ Preservation and Transplantation: A Narrative Review. Life (Basel) 2023; 14:65. [PMID: 38255680 PMCID: PMC10817660 DOI: 10.3390/life14010065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 12/19/2023] [Accepted: 12/27/2023] [Indexed: 01/24/2024] Open
Abstract
Cytokine adsorption can resolve different complications characteristic of transplantation medicine, such as cytokine storm activation and blood ABO and immune incompatibilities. Cytokine adsorption is also performed for the treatment of various life-threatening conditions, such as endotoxic septic shock, acute respiratory distress syndrome, and cardiogenic shock, all potentially leading to adverse clinical outcomes during transplantation. After surgery, dysmetabolism and stress response limit successful graft survival and can lead to primary or secondary graft dysfunction. In this clinical context, and given that a major problem in transplant medicine is that the demand for organs far exceeds the supply, a technological innovation such as a hemoadsorption system could greatly contribute to increasing the number of usable organ donors. The objectives of this review are to describe the specific advantages and disadvantages of the application of cytokine adsorption in the context of transplantation and examine, before and/or after organ transplantation, the benefits of the addition of a cytokine adsorption therapy protocol.
Collapse
Affiliation(s)
- Refugio García-Villegas
- Departamento de Fisiología, Biofísica y Neurociencias, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, D.F., Mexico City 07360, Mexico;
| | - Stephan Arni
- Department of Thoracic Surgery, University Hospital Zürich, 8091 Zürich, Switzerland
| |
Collapse
|
5
|
Forin E, Lorenzoni G, Ferrer R, De Cal M, Zanella M, Marchionna N, Gregori D, Forfori F, Lorenzin A, Danzi V, Ronco C, De Rosa S. Endotoxin removal therapy with Polymyxin B immobilized fiber column: a single center experience from EUPHAS2 registry. Sci Rep 2023; 13:17600. [PMID: 37845296 PMCID: PMC10579294 DOI: 10.1038/s41598-023-44850-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2023] [Accepted: 10/12/2023] [Indexed: 10/18/2023] Open
Abstract
Although the precise clinical indication for initiation of PMX-HA is widely debated in the literature, a proper patient selection and timing of treatment delivery might play a critical role in the clinical course of a specific subphenotype of septic shock (endotoxic shock). In light of this view, since 2019, we have introduced in our clinical practice a diagnostic-therapeutic flowchart to select patients that can benefit the most from the treatment proposed. In addition, we reported in this study our experience of PMX-HA in a cohort of critically ill patients admitted to our intensive care unit (ICU). We analyzed a single centre, retrospective, observational web-based database (extracted from the EUPHAS2 registry) of critically ill patients admitted to the ICU between January 2016 and May 2021 who were affected by endotoxic shock. Patients were divided according to the diagnostic-therapeutic flowchart in two groups: Pre-Flowchart (Pre-F) and Post-Flowchart (Post-F). From January 2016 to May 2021, 61 patients were treated with PMX-HA out of 531 patients diagnosed with septic shock and of these, fifty patients (82%) developed AKI during their ICU stay. The most common source of infection was secondary peritonitis (36%), followed by community-acquired pneumonia (29%). Fifty-five (90%) out of 61 patients received a second PMX-HA treatment, with a statistically significant difference between the two groups (78% of the Pre-F vs. 100% of the Post-F group, p = 0.005). In both groups, between T0 and T120, the Endotoxin Activity Assay (EAA) decreased, while the SOFA score, mean arterial pressure (MAP), and Vasoactive Inotropic Score (VIS) improved with no statistically significant difference. Furthermore, when performing a propensity score matching analysis to compare mortality between the two groups, statistically significant lower ICU and 90-day mortalities were observed in the Post-F group [p = 0.016]. Although in this experienced centre data registry, PMX-HA was associated with organ function recovery, hemodynamic improvement, and current EAA level reduction in critically ill patients with endotoxic shock. Following propensity score-matched analysis, ICU mortality and 90-day mortalities were lower in the diagnostic-therapeutic flowchart group when considering two temporal groups based on strict patient selection criteria and timing to achieve PMX. Further Randomised Control Trials focused on centre selection, adequate training and a flowchart of action when assessing extracorporeal blood purification use should be performed.
Collapse
Affiliation(s)
- Edoardo Forin
- International Renal Research Institute of Vicenza Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy
- Department of Anesthesiology and Intensive Care, San Bortolo Hospital, Vicenza, Italy
| | - Giulia Lorenzoni
- Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Ricard Ferrer
- Shock, Organ Dysfunction, and Resuscitation Research Group (SODIR), Institut de Recerca Vall d'Hebron (VHIR), Barcelona, Spain
- Intensive Care Department, Hospital Universitari Vall d́'Hebron, Barcelona, Spain
| | - Massimo De Cal
- International Renal Research Institute of Vicenza Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy
| | - Monica Zanella
- Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy
| | - Nicola Marchionna
- Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy
| | - Dario Gregori
- Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy
| | - Francesco Forfori
- Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, The University of Pisa, Pisa, Italy
| | - Anna Lorenzin
- International Renal Research Institute of Vicenza Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy
| | - Vinicio Danzi
- Department of Anesthesiology and Intensive Care, San Bortolo Hospital, Vicenza, Italy
| | - Claudio Ronco
- International Renal Research Institute of Vicenza Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy
- Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, Vicenza, Italy
| | - Silvia De Rosa
- International Renal Research Institute of Vicenza Institute of Vicenza, San Bortolo Hospital, Vicenza, Italy.
- Department of Anesthesiology and Intensive Care, San Bortolo Hospital, Vicenza, Italy.
- Centre for Medical Sciences - CISMed, University of Trento, Via S. Maria Maddalena 1, 38122, Trento, Italy.
| |
Collapse
|